Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Flatiron Health found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Flatiron Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Oncology data and software supplier; no regulatory or clinical safety actions found in the last 24 months.
Contract delivery, go-lives, terminations and disputes.
Jul 2026: Flatiron Health UK announced a research data partnership with NHS Greater Glasgow and Clyde, its first in Scotland, using AI and clinical abstractors to turn routine oncology records into research-ready datasets.